Metabolic response during preoperative chemotherapy can predict prognosis in pancreatic cancer

被引：0
作者：
Yun, Won-Gun [1 ,2 ]
Kim, Tae Young [3 ]
Park, Seulah [1 ,2 ]
Han, Youngmin [1 ,2 ]
Choi, Go-Won [1 ,2 ]
Jung, Hye-Sol [1 ,2 ]
Kwon, Wooil [1 ,2 ]
Park, Joon Seong [1 ,2 ]
Cheon, Gi Jeong [3 ,4 ,5 ,6 ]
Jang, Jin-Young [1 ,2 ]
机构：
[1] Seoul Natl Univ, Coll Med, Dept Surg, 28 Yongon Dong, Seoul 110744, South Korea
[2] Seoul Natl Univ, Canc Res Inst, Coll Med, 28 Yongon Dong, Seoul 110744, South Korea
[3] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul, South Korea
[4] Seoul Natl Univ, Coll Med, Dept Nucl Med, 28 Yongon Dong, Seoul 110744, South Korea
[5] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea
[6] Seoul Natl Univ, Inst Aging, Seoul, South Korea
来源：
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES | 2025年
关键词：
fluorodeoxyglucose F18; induction chemotherapy; neoadjuvant therapy; pancreatic neoplasms; positron-emission tomography; NEOADJUVANT THERAPY; ADENOCARCINOMA; GEMCITABINE; FOLFIRINOX; SURGERY;
D O I：
10.1002/jhbp.12122
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Background: With the evolving treatment paradigms for pancreatic cancer, there is an increasing need for reliable markers to evaluate the effectiveness of preoperative chemotherapy. Due to the limitations of current indicators, this study aimed to evaluate the prognostic value of metabolic response based on the changes in the maximum standardized uptake value (SUVmax) on fluorine-18-fluorodeoxyglucose positron emission tomography. Methods: This study included 210 patients with pancreatic cancer who underwent post-chemotherapy curative surgery between 2013 and 2022. Using maximally selected rank statistics for survival, the metabolic response was defined as follows: metabolic responder (%Delta SUVmax >75%), metabolic stable disease (15%-75%), and metabolic non-responder (<= 15%). Results: Among patients, 15.7%, 66.7%, and 11.6% were categorized into the metabolic responder, metabolic stable disease, and metabolic non-responder groups. The metabolic responder group (83.0 months) had longer median overall survival than the metabolic stable disease (51.0 months, p = .013) and metabolic non-responder (32.0 months, p = .002) groups. In addition, being metabolic responders (vs. non-responders) was an independent predictor of low recurrence rates (hazard ratio [95% confidence interval]: 0.46 [0.23-0.91]; p = .026) and achieving pathologic complete response (odds ratio [95% confidence interval]: 13.39 [1.61-300.77]; p = .035). Conclusions: Metabolic response during preoperative chemotherapy has predictive power for post-resection prognosis and residual tumor status.
引用
收藏
页数：11
相关论文
共 30 条
  • [1] Siegel R.L., Giaquinto A.N., Jemal A., Cancer statistics, 2024, CA Cancer J Clin, 74, pp. 12-49, (2024)
  • [2] Jang J.Y., Han Y., Lee H., Kim S.W., Kwon W., Lee K.H., Et al., Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial, Ann Surg, 268, pp. 215-222, (2018)
  • [3] Versteijne E., van Dam J.L., Suker M., Janssen Q.P., Groothuis K., Akkermans-Vogelaar J.M., Et al., Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial, J Clin Oncol, 40, pp. 1220-1230, (2022)
  • [4] Ghaneh P., Palmer D., Cicconi S., Jackson R., Halloran C.M., Rawcliffe C., Et al., Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial, Lancet Gastroenterol Hepatol, 8, pp. 157-168, (2023)
  • [5] Seufferlein T., Uhl W., Kornmann M., Algul H., Friess H., Konig A., Et al., Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group, Ann Oncol, 34, pp. 91-100, (2023)
  • [6] Labori K.J., Bratlie S.O., Andersson B., Angelsen J.H., Biorserud C., Bjornsson B., Et al., Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial, Lancet Gastroenterol Hepatol, 9, pp. 205-217, (2024)
  • [7] Lee M., Kang J.S., Kim H., Kwon W., Lee S.H., Ryu J.K., Et al., Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy, J Hepatobiliary Pancreat Sci, 30, pp. 111-121, (2023)
  • [8] Nassour I., Parrish A., Baptist L., Voskamp S., Handoo K., Rogers S., Et al., National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer, HPB (Oxford), 25, pp. 1323-1328, (2023)
  • [9] Katz M.H., Fleming J.B., Bhosale P., Varadhachary G., Lee J.E., Wolff R., Et al., Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators, Cancer, 118, pp. 5749-5756, (2012)
  • [10] Cassinotto C., Cortade J., Belleannee G., Lapuyade B., Terrebonne E., Vendrely V., Et al., An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment, Eur J Radiol, 82, pp. 589-593, (2013)
123